Amphista Therapeutics Ltd. has announced new datasets with its next-generation bifunctional protein degraders demonstrating in vivo efficacy and the ability to target and degrade proteins in the central nervous system (CNS).
Increased expression of B7-H3 has been previously reported in multiple solid tumors, including pancreatic cancer. In a recent article, researchers from the University of Tuebingen discussed the development of a novel Fc-optimized monoclonal antibody (MAb) targeting B7-H3, named B7-H3-SDIE, as a new immunotherapeutic treatment option for pancreatic cancer.
Medshine Discovery Inc. has synthesized amino-substituted heteroaryl derivatives acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
CDR-Life Inc. has announced FDA clearance of an IND application for CDR-404, its lead program in development as a precision immunotherapy for solid tumors.
NK Celltech Co. Ltd. has announced FDA clearance for a clinical trial of NK-010, a nongenetically modified allogeneic peripheral blood natural killer (NK) cell drug.
Strand Therapeutics Inc. has received IND clearance from the FDA to initiate a first-in-human phase I trial of STX-001 as a new approach for the treatment of solid tumors.
Simultaneous inhibition of the phosphoinositide 3-kinase (PI3K) signaling pathway and histone deacetylase (HDAC) provides synergistic efficacy in the treatment of hematological malignancies.
Despite treatment with temozolomide and radiation therapy, patients with glioblastoma usually develop refractory disease, and thus have a poor prognosis (median overall survival of 15 months); here, the DNA damage response (DDR) mechanism shown by cancer cells plays a key role.
Chinese researchers have presented data on a novel six-gene prognostic risk model for breast cancer based on data from the The Cancer Genome Atlas (TCGA) database.
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive form of leukemia that accounts for around 25% of ALL cases. In recent years, novel strategies have emerged to reduce the dependence on intensive chemotherapy or hematopoietic stem cell transplantation, but there is still a need for new options with better efficacy in this setting.
RSS
